Why Choose Our Psoriasis Research Platform
Psoriasis is a chronic immune-mediated inflammatory skin disorder characterized by keratinocyte hyperproliferation, epidermal thickening, immune cell infiltration, and dysregulated cytokine signaling involving pathways such as IL-17, IL-23, TNF-α, and JAK/STAT. The complexity of disease biology requires robust experimental models that can support target validation, compound screening, and preclinical efficacy testing.
Ace Therapeutics provides comprehensive psoriasis research services using in vitro, ex vivo, and in vivo models to help biotechnology companies, pharmaceutical developers, and academic researchers accelerate therapeutic innovation. Our customized preclinical solutions are designed to support programs from early discovery through drug candidate evaluation.
- Comprehensive Psoriasis Models: We offer a full range of psoriasis models, including cellular assays and animal models, enabling progression from early screening to preclinical efficacy studies.
- Support for Multiple Therapeutic Modalities: Our platform is compatible with small molecules, monoclonal antibodies, peptides, topical formulations, RNA therapeutics, and microbiome-based products.
- Customized Study Design: Each project is tailored based on therapeutic target, mechanism of action, development stage, budget, and timeline.
- Comprehensive Readout Capabilities: We provide histology, cytokine analysis, molecular profiling, imaging, immunological characterization, and other endpoints.
Comprehensive Psoriasis Models We Offer
In Vitro Psoriasis Model
-
- Cytokine-Induced Keratinocyte
- Immune Cell Co-Culture Model
- 3D Psoriatic Skin Model
In Vivo Psoriasis Model
- Spontaneous Models of Psoriasis
- Genetically Engineered Psoriasis Model
- IL-23-Induced Psoriasis Model
- Propranolol-Induced Psoriasis-Like Model
- Humanized Mouse Psoriasis Model
- Imiquimod-Induced Psoriasis Model
- Mannan-Induced Psoriatic Arthritis Models
- Xenotransplantation Models of Psoriasis Development Services
- Estrogen-Induced Vaginal Epithelium Psoriasis-Like Model
Selecting the most suitable psoriasis model is essential for generating reliable and decision-oriented preclinical data. Different model systems provide distinct advantages depending on whether the objective is rapid screening, mechanism validation, efficacy confirmation, translational assessment, or topical formulation development. An integrated strategy combining in vitro, ex vivo, and in vivo models is often the most efficient approach for psoriasis drug discovery.
| Model | Type | Species | Advantages | Applications |
| Cytokine-Induced Keratinocyte Model | In Vitro | - |
|
|
| 3D Psoriatic Skin Model | In Vitro | - |
|
|
| Human Skin Explant Model | Ex Vivo | - |
|
|
| Imiquimod-Induced Psoriasis Model | In Vivo | Mouse, NHP |
|
|
| IL-23-Induced Mouse Model | In Vivo | Mouse, pig |
|
|
| Transgenic Mouse Models | In Vivo | Mouse. pig |
|
|
Psoriasis Model Establishment Workflow
A standardized and reproducible workflow to establish and evaluate psoriasis models for preclinical research.
01 Cell Preparation
Seed keratinocytes and/or immune cells and culture under appropriate conditions.
02 Model Development
Establish the in vitro pooriasis model (2D culture, 3D skin equivalent, or co-culture system).
03 Cell Activation / Stimulation
Stimulate cells with psoriasis-related cytokines or stimuli (e.g, IL-17A, IL-22, TNF-α) for a defined period.
04 Model Validation
Confirm model establishment by evaluating psoriasis-related biomarkers and phenotypic changes.
05 Treatment / Intervention
Treat the model with test compounds, reference drugs, or vehicle controls at defined concentrations.
06 Endpoint Assessment
Assess endpoints including gene/protein expression, cytokine secretion, cell proliferation, differentiation, and barrier function.
07 Data Analysis & Reporting
Analyze data and generate reports to support research and decision-making.
01 Animal Preparation
Shave the dorsal skin and allow animals to acclimate before study initiation.
02 Model Preparation
Prepare psoriasis-inducing agents, cytokines, formulations, and dosing materials.
03 Psoriasis Induction
Induce psoriasis-like skin inflammation using defined agents or cytokine treatments.
04 Model Validation
Confirm model establishment by evaluating erythema, scaling, skin thickening, and other psoriasis-related features.
05 Disease Monitoring
Monitor disease progression, body weight, and clinical scores throughout the study.
06 Sample Collection
Collect skin, blood, lymphoid tissues, and other study samples at designated time points.
07 Endpoint Analysis
Perform histological, molecular, and immunological analyses and evaluate study data.
Key Endpoints for Psoriasis Model Studies
We offer flexible endpoints tailored to your scientific objectives and development stage.
Clinical Endpoints
- Erythema
- Scaling
- Skin thickness
- PASI-like scoring
Histology
- Epidermal hyperplasia
- Immune infiltration
- Keratinocyte proliferation
Molecular Biomarkers
- IL-17A
- IL-23
- TNF-α
- IL-6
Imaging
- H&E staining
- Immunohistochemistry
- Immunofluorescence
Therapeutic Modalities We Support
Our psoriasis models are suitable for evaluating a broad range of therapeutic candidates.
Small Molecules
- TYK2 inhibitors
- JAK inhibitors
- PDE4 inhibitors
- Kinase inhibitors
Biologics
- Anti-IL-17 antibodies
- Anti-IL-23 antibodies
- TNF inhibitors
- Fusion proteins
Topical Antipsoriatic Drugs
- Creams
- Gels
- Ointments
- Sprays
- Sustained-release formulations
Other Therapeutics
RNA therapeutics, peptides, microbiome products
How to Select the Right Psoriasis Model for Drug Development
Selecting the optimal model depends on therapeutic modality, biological target, timeline, and development objective.
For Rapid Compound Screening
Use cytokine-induced keratinocytes or imiquimod mouse models to conduct an efficient efficacy study.
For Mechanism-of-Action Studies
Use immune co-culture models, IL-23-induced mouse models, or genetically engineered animals.
For Topical Product Development
3D reconstructed skin, human explants, and pig skin models are highly recommended.
Frequently Asked Questions
What is the most commonly used psoriasis mouse model?
The imiquimod-induced mouse model is one of the most widely used systems for anti-inflammatory efficacy testing.
Can you support biologics and small molecule programs?
Yes. We routinely support antibodies, proteins, peptides, oral compounds, and topical candidates.
Can endpoints be customized?
Absolutely. Histology, cytokines, imaging, flow cytometry, sequencing, and other endpoints can be integrated based on project goals.
You might be interested in...
Start Your Antipsoriatic Drug Development Program Today
Whether you are evaluating an early lead or optimizing a clinical candidate, our psoriasis models and drug development services can help accelerate progress with reliable data and expert execution. Share your target, modality, preferred model, and timeline. Our scientific team will recommend a customized study plan aligned with your program goals.